Llwytho...
Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma
Cancers of the stomach and gastro-esophageal junction represent a significant challenge in oncology. Despite some recent advances in genetic categorization and the development of novel agents, outcomes remain poor. The vascular endothelial growth factor receptor 2 monoclonal antibody ramucirumab is...
Wedi'i Gadw mewn:
Cyhoeddwyd yn: | Onco Targets Ther |
---|---|
Prif Awduron: | , , |
Fformat: | Artigo |
Iaith: | Inglês |
Cyhoeddwyd: |
Dove Medical Press
2016
|
Pynciau: | |
Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4966750/ https://ncbi.nlm.nih.gov/pubmed/27524910 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S84153 |
Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|